Volume: 2 Issue: 2
Year: 2025, Page: 52-59, Doi: https://doi.org/10.71325/ajjms.v2i2.25.19
Received: March 26, 2025 Accepted: May 16, 2025 Published: July 16, 2025
A significant amount of the health care burden in contemporary society is attributed to neurodegenerative diseases (NDs). Because of longer lifespans and changes in the world's population, the prevalence of these diseases will rise even more in the future decades. The primary cause of NDs is the progressive degeneration of neurones, which leads to dementia, motor impairments, and other associated functional impairments. Numerous illnesses, including Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), and Amyotrophic Lateral Sclerosis (ALS), are brought on by these alterations. Neurone death, dendritic loss, and demyelination are general pathophysiological indicators. Furthermore, a number of molecular processes have been postulated to explain the pathophysiology of these disorders, while the precise reason is still unknown. Neuroinflammation and oxidative stress are the most prevalent. With regard to neuroinflammation, we attempt to draw attention to a neglected factor in the aetiology of multiple sclerosis in this review. Protein domains found in a number of bacteria imitate the cellular proteins found in the nervous system. As a result, even when the viruses are removed from the body, the immune system never stops functioning. Native proteins are nonetheless regarded as alien proteins, and the cells die as a result of subsequent immune cell activation and communication. As a result, we have compiled the research supporting this theory to link it to other chemical pathways in NDs.
Keywords: Immune system, Autoimmunity, Multiple Sclerosis, Molecular Mimicry, Neurodegenerative Diseases (NDs)
Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–1783. Available from: https://dx.doi.org/10.1212/wnl.0b013e31828726f5
DeMaio A, Mehrotra S, Sambamurti K, Husain S. The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases. Journal of Neuroinflammation. 2022;19(1):1–19. Available from: https://dx.doi.org/10.1186/s12974-022-02605-9
Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. Journal of the Neurological Sciences. 2013;333(1-2):76–87. Available from: https://doi.org/10.1016/j.jns.2013.03.002
Rostgaard K, Balfour HH, Jarrett R, Erikstrup C, Pedersen O, Ullum H, et al. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLOS ONE. 2019;14(12):1–14. Available from: https://dx.doi.org/10.1371/journal.pone.0226436
Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nature Reviews Immunology. 2004;4(1):55–66. Available from: https://doi.org/10.1038/nri1264
Tran VTA, Lee LP, Cho H. Neuroinflammation in neurodegeneration via microbial infections. Frontiers in Immunology. 2022;13:1–18. Available from: https://dx.doi.org/10.3389/fimmu.2022.907804
DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. Journal of Neurochemistry. 2016;139(S2):136–153. Available from: https://dx.doi.org/10.1111/jnc.13607
Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nature Reviews Immunology. 2014;14(7):463–477. Available from: https://doi.org/10.1038/nri3705
Fymat AL. Multiple Sclerosis: I. Symptomatology and Etiology. Journal of Neurology and Psychology Research. 2023;4(1):1–46. Available from: https://researchnovelty.com/management_research/article_pdf/1684580323Updated%20Article__CS050523.pdf
Ziemssen T, Bhan V, Chataway J, Chitnis T, Cree BAC, Havrdova EK, et al. Secondary progressive multiple sclerosis: a review of clinical characteristics, definition, prognostic tools, and disease-modifying therapies. Neurology: Neuroimmunology & Neuroinflammation. 2022;10(1):1–12. Available from: https://doi.org/10.1212/nxi.0000000000200064
Miller DH, Leary SM. Primary-progressive multiple sclerosis. The Lancet Neurology. 2007;6(10):903–912. Available from: https://doi.org/10.1016/S1474-4422(07)70243-0
Kalinowska-Łyszczarz A, Guo Y, Lucchinetti CF. Update on pathology of central nervous system inflammatory demyelinating diseases. Neurologia i neurochirurgia polska. 2022;56(3):201–209. Available from: https://doi.org/10.5603/pjnns.a2022.0046
Hafler DA, Weiner HL. T Cells in Multiple Sclerosis and Inflammatory Central Nervous System Diseases. Immunological Reviews. 1987;100(1):307–332. Available from: https://dx.doi.org/10.1111/j.1600-065x.1987.tb00537.x
Arango MT, Perricone C, Kivity S, Cipriano E, Ceccarelli F, Valesini G, et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunologic Research. 2017;65(1):82–98. Available from: https://dx.doi.org/10.1007/s12026-016-8817-7
Parnell GP, Booth DR. The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities. Frontiers in Immunology. 2017;8:1–6. Available from: https://dx.doi.org/10.3389/fimmu.2017.00425
Marrodan M, Alessandro L, Farez MF, Correale J. The role of infections in multiple sclerosis. Multiple Sclerosis Journal. 2019;25(7):891–901. Available from: https://dx.doi.org/10.1177/1352458518823940
Dobson R, Giovannoni G. Multiple sclerosis – a review. European Journal of Neurology. 2019;26(1):27–40. Available from: https://dx.doi.org/10.1111/ene.13819
Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018;97(4):742–768. Available from: https://dx.doi.org/10.1016/j.neuron.2018.01.021
Donati D. Viral infections and multiple sclerosis. Drug Discovery Today: Disease Models. 2020;32(Part A):27–33. Available from: https://doi.org/10.1016/j.ddmod.2020.02.003
Cortese M, Leng Y, Bjornevik K, Mitchell M, Healy BC, Mina MJ, et al. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis. JAMA Neurology. 2024;81(5):515–524. Available from: https://dx.doi.org/10.1001/jamaneurol.2024.0272
Vlad B, Neidhart S, Hilty M, Högelin KA, Reichen I, Ziegler M, et al. Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis. Multiple Sclerosis Journal. 2024;30(13):1598–1608. Available from: https://dx.doi.org/10.1177/13524585241279645
Rani A, Ergün S, Karnati S, Jha HC. Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis. Journal of NeuroVirology. 2024;30(1):22–38. Available from: https://dx.doi.org/10.1007/s13365-023-01190-8
Agostini S, Mancuso R, Costa AS, Citterio LA, Guerini FR, Meloni M, et al. A Possible Role for HSV-1-Specific Humoral Response and PILRA rs1859788 Polymorphism in the Pathogenesis of Parkinson’s Disease. Vaccines. 2021;9(7):1–10. Available from: https://dx.doi.org/10.3390/vaccines9070686
Komaroff AL, Pellett PE, Jacobson S. Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation. Clinical Microbiology Reviews. 2020;34(1):1–36. Available from: https://dx.doi.org/10.1128/cmr.00143-20
Hera BDL, Urcelay E. HERVs in Multiple Sclerosis — From Insertion to Therapy. In: Open ac. (p. 169) 2016.
Houen G, Trier NH, Frederiksen JL. Epstein-Barr Virus and Multiple Sclerosis. Frontiers in immunology. 2020;11:1–11. Available from: https://doi.org/10.3389/fimmu.2020.587078
Jha NK, Ojha S, Jha SK, Dureja H, Singh SK, Shukla SD, et al. Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. Journal of Molecular Neuroscience. 2021;71(11):2192–2209. Available from: https://doi.org/10.1007/s12031-020-01767-6
Bellucci G, Rinaldi V, Buscarinu MC, Reniè R, Bigi R, Pellicciari G, et al. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Frontiers in Immunology. 2021;12:1–14. Available from: https://doi.org/10.3389/fimmu.2021.755333
Frau J, Coghe G, Lorefice L, Fenu G, Cocco E. Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World. Frontiers in Immunology. 2021;12:1–7. Available from: https://dx.doi.org/10.3389/fimmu.2021.728677
James RE, Schalks R, Browne E, Eleftheriadou I, Munoz CP, Mazarakis ND, et al. Persistent elevation of intrathecal pro-inflammatory cytokines leads to multiple sclerosis-like cortical demyelination and neurodegeneration. Acta Neuropathologica Communications. 2020;8(1):1–18. Available from: https://dx.doi.org/10.1186/s40478-020-00938-1
Libbey JE, Cusick MF, Fujinami RS. Role of Pathogens in Multiple Sclerosis. International Reviews of Immunology. 2014;33(4):266–283. Available from: https://dx.doi.org/10.3109/08830185.2013.823422
Kang GG, Trevaskis NL, Murphy AJ, Febbraio MA. Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH. iScience. 2023;26:1–23. Available from: https://dx.doi.org/10.1016/j.isci.2022.105905
Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200. Available from: https://dx.doi.org/10.1080/19490976.2015.1134082
Rutsch A, Kantsjö JB, Ronchi F. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Front Immunol. 2020;11:1–24. Available from: https://doi.org/10.3389/fimmu.2020.604179
Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. Acta Paediatrica Suppl. 1994;407:86–88. Available from: https://doi.org/10.1111/j.1651-2227.1994.tb13461.x
He W, Wu G. Metabolism of Amino Acids in the Brain and Their Roles in Regulating Food Intake. Amino Acids in Nutrition and Health. 2020:167–185. Available from: https://doi.org/10.1007/978-3-030-45328-2_10
Gao Y, Zhou J, Qi H, Wei J, Yang Y, Yue J, et al. LncRNA lncLy6C induced by microbiota metabolite butyrate promotes differentiation of Ly6Chigh to Ly6Cint/neg macrophages through lncLy6C/C/EBPβ/Nr4A1 axis. Cell Discovery. 2020;6(1):1–14. Available from: https://dx.doi.org/10.1038/s41421-020-00211-8
Turner TAA, Lehman P, Ghimire S, Shahi SK, Mangalam A. Game of microbes: the battle within – gut microbiota and multiple sclerosis. Gut Microbes. 2024;16(1):1–25. Available from: https://doi.org/10.1080/19490976.2024.2387794
Na K, Oh BC, Jung Y. Multifaceted role of CD14 in innate immunity and tissue homeostasis. Cytokine & Growth Factor Reviews. 2023;74:100–107. Available from: https://dx.doi.org/10.1016/j.cytogfr.2023.08.008
Sterling KG, Dodd GK, Alhamdi S, Asimenios PG, Dagda RK, Meirleir KLD, et al. Mucosal Immunity and the Gut-Microbiota-Brain-Axis in Neuroimmune Disease. International Journal of Molecular Sciences. 2022;23(21):1–35. Available from: https://dx.doi.org/10.3390/ijms232113328
Anand N, Gorantla VR, Chidambaram SB. The Role of Gut Dysbiosis in the Pathophysiology of Neuropsychiatric Disorders. Cells. 2022;12(1):1–30. Available from: https://dx.doi.org/10.3390/cells12010054
Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences. 2017;114(40):10713–10718. Available from: https://dx.doi.org/10.1073/pnas.1711235114
Pröbstel AK, Zhou X, Baumann R, Wischnewski S, Kutza M, Rojas OL, et al. Gut microbiota–specific IgA+ B cells traffic to the CNS in active multiple sclerosis. Science Immunology. 2020;5(53). Available from: https://doi.org/10.1126/sciimmunol.abc7191
Stanisavljević S, Čepić A, Bojić S, Veljović K, Mihajlović S, Đedović N, et al. Oral neonatal antibiotic treatment perturbs gut microbiota and aggravates central nervous system autoimmunity in Dark Agouti rats. Scientific Reports. 2019;9(1):1–13. Available from: https://dx.doi.org/10.1038/s41598-018-37505-7
Arpaia N, Campbell C, Fan X, Dikiy S, Veeken Jvd, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455. Available from: https://dx.doi.org/10.1038/nature12726
Correale J, Hohlfeld R, Baranzini SE. The role of the gut microbiota in multiple sclerosis. Nature Reviews Neurology. 2022;18(9):544–558. Available from: https://dx.doi.org/10.1038/s41582-022-00697-8
Jadidi‐Niaragh F, Mirshafiey A. Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis. Scandinavian Journal of Immunology. 2011;74(1):1–13. Available from: https://dx.doi.org/10.1111/j.1365-3083.2011.02536.x
Mentis AFA, Dardiotis E, Grigoriadis N, Petinaki E, Hadjigeorgiou GM. Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Molecular Neurobiology. 2017;54(5):3911–3923. Available from: https://dx.doi.org/10.1007/s12035-017-0530-6
© 2025 Published by Laxmi Memorial Education Trust. This is an open-access article under CC BY 4.0 license. (https://creativecommons.org/licenses/by/4.0/)
B Nayana, K C Sandeep, N S Uzma. The Microbiome-Neurodegeneration Nexus in Multiple Sclerosis. AJ J Med Sci 2025;2(2):52–59.